Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …

Protease inhibitors (PIs) function as a natural adversary to proteolytic enzymes. They can
diminish or inhibit the catalytic properties of proteases, which are crucial for various tasks in …

Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells
in the bone marrow (BM). MM remains an incurable disease, with the majority of patients …

The ubiquitin-proteasome pathway (UPP) is the major proteolytic system in the cytosol and
nucleus of all eukaryotic cells. The role of proteasome inhibitors (PIs) as critical agents for …

Multiple myeloma (MM), a cancer of plasma cells, is the second most common
hematological malignancy which is characterized by aberrant plasma cells infiltration in the …

Multiple myeloma (MM), the second most common hematological malignancy, is a disease
characterized by a clonal expansion of malignant plasma cells that accumulate in the bone …

The proteasome regulates intracellular processes, maintains biological homeostasis, and
has shown great significance in the study of various diseases, such as neurodegenerative …

Highlights•Hematological malignancies comprise 1.2 million new cases annually
worldwide.•Current treatment options are limited by cancer cell resistance and relapse …

Proteasome inhibitors are moieties targeting the proteolytic activity of a proteasome, with
demonstrated efficacy in certain hematological malignancies and candidate drugs in other …

The ubiquitin‐proteasome pathway (UPP) represents the principal proteolytic apparatus in
the cytosol and nucleus of all eukaryotic cells. Nowadays, proteasome inhibitors (PIs) are …